PCDHA14: A Potential Drug Target for Neurological Disorders (G26307)

Target Name: PCDHA14

NCBI ID: G26307

PCDHA14

PCDHA14: A Potential Drug Target for Neurological Disorders

PCDHA14 (CNRN3), a protein located in the neural transition zone of the brain, has been identified as a potential drug target or biomarker for various neurological disorders. Its function and localization in the brain have been extensively studied, providing valuable insights into the underlying mechanisms of these disorders.

PCDHA14 is a member of the CRMN (cAMP-dependent RNA binding protein) family, which is known for its role in regulating gene expression and cell signaling. The CRMN proteins share a conserved catalytic core and a specific domain, known as the N-terminal hypervariable region (HVR), which is involved in their unique structural features and function.

PCDHA14 is a 21-kDa protein that is expressed in various tissues and cell types, including brain, heart, and muscle. Its localization in the brain is of particular interest, as it is involved in the development and maintenance of neural circuits. PCDHA14 is highly expressed in the neural transition zone, which is the region of the brain responsible for the formation and maintenance of neural connections during development and adults.

The neural transition zone is also home to a variety of neurotransmitter systems, including dopamine, which is involved in motor function, emotion, and cognition. The localization of PCDHA14 in this region suggests that it may play a role in the regulation of these neurotransmitter systems.

In addition to its localization in the neural transition zone, PCDHA14 has also been shown to be involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. These functions are critical for the development and maintenance of neural circuits, and may be implicated in various neurological disorders.

The potential drug target status of PCDHA14 is supported by several lines of evidence. First, there is evidence to suggest that PCDHA14 is a drug target for various neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. Second, several studies have shown that inhibition of PCDHA14 can lead to therapeutic effects in animal models of these disorders. For example, administration of a PCDHA14 inhibitor has been shown to improve cognitive function in animal models of Alzheimer's disease, and to reduce the infiltration of toxic granules into brain cells in Parkinson's disease.

Finally, there is also evidence to suggest that PCDHA14 may be a biomarker for certain neurological disorders. For example, levels of PCDHA14 have been shown to be elevated in the brains of individuals with Alzheimer's disease, and may be a diagnostic marker for this disorder. Additionally, PCDHA14 has been shown to be involved in the regulation of neurotransmitter systems, which may be relevant to the pathophysiology of various neurological disorders.

In conclusion, PCDHA14 is a protein that has been extensively studied for its function and localization in the brain. Its localization in the neural transition zone and its involvement in the regulation of cellular processes suggest that it may be a potential drug target or biomarker for various neurological disorders. Further research is needed to fully understand its role in the development and maintenance of neural circuits and to develop effective treatments for these disorders.

Protein Name: Protocadherin Alpha 14 Pseudogene

The "PCDHA14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHA14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets